{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:05:11Z","timestamp":1794557111627,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shaanxi Provincial Health Scientific Research Innovation Platform Project","award":["2025PT-07"],"award-info":[{"award-number":["2025PT-07"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073361"],"award-info":[{"award-number":["82073361"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2025JC-QYCX-065"],"award-info":[{"award-number":["2025JC-QYCX-065"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers","award":["2025GTEP011"],"award-info":[{"award-number":["2025GTEP011"]}]},{"name":"Cross-Disciplinary Integration Initiative of Air Force Medical University","award":["2024JC006"],"award-info":[{"award-number":["2024JC006"]}],"id":[{"id":"https:\/\/ror.org\/00ms48f15","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Medical Research Project of the Innovation Research Institute of Xijing Hospital","award":["LHJJ2024JH36"],"award-info":[{"award-number":["LHJJ2024JH36"]}],"id":[{"id":"https:\/\/ror.org\/05cqe9350","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shaanxi Provincial Key R&D Program","award":["2024SF-YBXM-221"],"award-info":[{"award-number":["2024SF-YBXM-221"]}]},{"name":"Special Support Program for High-Level Talents in Shaanxi Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) immunotherapy is limited by antigenic heterogeneity and an immunosuppressive microenvironment. This study engineered chimeric antigen receptor macrophages (CAR-Ms) targeting stress-inducible NKG2D ligands (NKG2DLs), broadly overexpressed in HCC, to enhance phagocytic clearance and remodel immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NKG2DL expression in HCC and association with survival were analyzed. CAR-Ms were constructed by fusing the NKG2D extracellular domain to Fc\u03b3RI signaling. In vitro assays assessed phagocytosis, cytokine secretion, signaling, and T cell interactions. Therapeutic efficacy was evaluated in immunocompetent mice bearing subcutaneous, orthotopic, or metastatic HCC models, with or without anti-PD-L1. Tumor progression, immunity, and survival were analyzed via bioluminescence imaging, flow cytometry, histopathology, and serum biochemistry. Statistics analyses were performed using t-tests, ANOVA, and log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NKG2DLs were significantly upregulated in human HCC and correlated with poor prognosis. CAR-Ms selectively engulfed NKG2DL\u207a tumor cells, polarized to an M1 phenotype, and activated PI3K-AKT and cGAS-STING pathways, driving phagocytosis and pro-inflammatory cytokines secretion. They enhanced T cell chemokines (Cxcl10, Ccl5) and antigen presentation, boosting T cell recruitment and activation in vitro. In subcutaneous models, CAR-Ms suppressed tumor growth, reprogrammed tumor-associated myeloid cells toward M1, and induced durable immune memory (100% tumor rejection upon rechallenge), with T cell activation. In orthotopic models, CAR-M monotherapy induced complete regression by week 5 and 100% survival, with elevated CD8\u207a T cells and CAR-M specifically homing to liver tumors. CAR-Ms suppressed metastasis in peritoneal\/pulmonary models. Combining CAR-Ms with PD-L1 blockade accelerated tumor clearance and survival versus monotherapies, enhancing T cell cytotoxicity. Safety assessments showed no significant organ toxicity based on histopathology and serum biochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NKG2D-directed CAR-Ms eliminate HCC through integrated innate phagocytosis, adaptive immune activation, and myeloid reprogramming, overcoming key therapeutic barriers. Combination with anti-PD-L1 enhances therapeutic efficacy by leveraging innate-adaptive crosstalk, providing a promising approach for HCC immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02538-w","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:17:39Z","timestamp":1765595859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Zihao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lequn","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"2538_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nature Reviews Disease Primers"},{"key":"2538_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","volume":"154","author":"X-F Xu","year":"2019","unstructured":"Xu X-F, Xing H, Han J, Li Z-L, Lau W-Y, Zhou Y-H, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: A multicenter study from China. JAMA Surg. 2019;154:209\u201317. https:\/\/doi.org\/10.1001\/jamasurg.2018.4334.","journal-title":"JAMA Surg"},{"key":"2538_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(18)30010-2.","journal-title":"Lancet"},{"key":"2538_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380. https:\/\/doi.org\/10.1002\/hep.29086.","journal-title":"Hepatology"},{"key":"2538_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835\u201353. https:\/\/doi.org\/10.1053\/j.gastro.2015.12.041.","journal-title":"Gastroenterology"},{"key":"2538_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, et al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:58. https:\/\/doi.org\/10.1186\/s12943-023-01725-x.","journal-title":"Mol Cancer"},{"key":"2538_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525\u201343. https:\/\/doi.org\/10.1038\/s41575-021-00438-0.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2538_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.matbio.2013.10.009","volume":"35","author":"MD Stewart","year":"2014","unstructured":"Stewart MD, Sanderson RD. Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biol J Int Soc Matrix Biol. 2014;35:56\u20139. https:\/\/doi.org\/10.1016\/j.matbio.2013.10.009.","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"key":"2538_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21:524\u20139. https:\/\/doi.org\/10.1038\/nm.3833.","journal-title":"Nat Med"},{"key":"2538_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"2538_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03342-6","volume":"20","author":"H Yang","year":"2022","unstructured":"Yang H, Yan M, Li W, Xu L. SIRP\u03b1 and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma. J Transl Med. 2022;20:140. https:\/\/doi.org\/10.1186\/s12967-022-03342-6.","journal-title":"J Transl Med"},{"key":"2538_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"key":"2538_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41587-025-02629-5","volume":"43","author":"M Tarannum","year":"2025","unstructured":"Tarannum M, Ding X, Barisa M, Hu S, Anderson J, Romee R, et al. Engineering innate immune cells for cancer immunotherapy. Nat Biotechnol. 2025;43:516\u201333. https:\/\/doi.org\/10.1038\/s41587-025-02629-5.","journal-title":"Nat Biotechnol"},{"key":"2538_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li N, Geng S, Dong Z, Jin Y, Ying H, Li H-W, et al. !!A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23:117. https:\/\/doi.org\/10.1186\/s12943-024-02032-9.","journal-title":"Mol Cancer"},{"key":"2538_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12:86. https:\/\/doi.org\/10.1186\/s40364-024-00637-2.","journal-title":"Biomark Res"},{"key":"2538_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00097","author":"J Zhang","year":"2015","unstructured":"Zhang J, Basher F, Wu JD. NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol. 2015. https:\/\/doi.org\/10.3389\/fimmu.2015.00097.","journal-title":"Front Immunol"},{"key":"2538_CR17","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1038\/sj.onc.1208825","volume":"24","author":"S-J Jeong","year":"2005","unstructured":"Jeong S-J, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. Activated AKT regulates NF-\u03baB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene Nat Publishing Group. 2005;24:6719\u201328. https:\/\/doi.org\/10.1038\/sj.onc.1208825.","journal-title":"Oncogene Nat Publishing Group"},{"key":"2538_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","volume":"21","author":"H Zhang","year":"2024","unstructured":"Zhang H, Huo Y, Zheng W, Li P, Li H, Zhang L, et al. Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors. Cell Mol Immunol. 2024;21:1335\u201349. https:\/\/doi.org\/10.1038\/s41423-024-01220-3.","journal-title":"Cell Mol Immunol"},{"key":"2538_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8:539\u201351. https:\/\/doi.org\/10.1016\/j.apsb.2018.03.001.","journal-title":"Acta Pharm Sin B"},{"key":"2538_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","journal-title":"Nat Med"},{"key":"2538_CR21","doi-asserted-by":"publisher","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol OncolJ Hematol Oncol J Hematol Oncol. 2024;17. https:\/\/doi.org\/10.1186\/s13045-024-01625-7. Cited 17 May 2025.","DOI":"10.1186\/s13045-024-01625-7"},{"key":"2538_CR22","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36688","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018. https:\/\/doi.org\/10.7554\/eLife.36688.","journal-title":"Elife"},{"key":"2538_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","volume":"21","author":"Y Huo","year":"2023","unstructured":"Huo Y, Zhang H, Sa L, Zheng W, He Y, Lyu H, et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Transl Med. 2023;21:225. https:\/\/doi.org\/10.1186\/s12967-023-04061-2.","journal-title":"J Transl Med"},{"key":"2538_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13:153. https:\/\/doi.org\/10.1186\/s13045-020-00983-2.","journal-title":"J Hematol Oncol"},{"key":"2538_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","volume":"31","author":"Z Shah","year":"2024","unstructured":"Shah Z, Tian L, Li Z, Jin L, Zhang J, Li Z, et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell. 2024;31:803-817.e6. https:\/\/doi.org\/10.1016\/j.stem.2024.03.018.","journal-title":"Cell Stem Cell"},{"key":"2538_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25:102\u201316. https:\/\/doi.org\/10.1038\/s41590-023-01687-8.","journal-title":"Nat Immunol"},{"key":"2538_CR27","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Su S, Zhu Y, Cheng X, Cheng C, Chen L, et al. Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat Commun. 2023;14:5778. https:\/\/doi.org\/10.1038\/s41467-023-41470-9.","journal-title":"Nat Commun"},{"key":"2538_CR28","unstructured":"Z FD et al. Y, A H, J Y, M S, Q J,. An engineered \u03b11\u03b21 integrin-mediated Fc\u03b3RI signaling component to control enhanced CAR macrophage activation and phagocytosis. PubMed. 2025; https:\/\/pubmed.ncbi.nlm.nih.gov\/39617174\/. Accessed 17 May 2025. Cited 17 May 2025."},{"key":"2538_CR29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2\u2009+\u2009solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16:706. https:\/\/doi.org\/10.1038\/s41467-024-55770-1.","journal-title":"Nat Commun"},{"key":"2538_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33:e2103258. https:\/\/doi.org\/10.1002\/adma.202103258.","journal-title":"Adv Mater"},{"key":"2538_CR31","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","volume":"18","author":"C Tang","year":"2024","unstructured":"Tang C, Jing W, Han K, Yang Z, Zhang S, Liu M, et al. mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model. ACS Nano. 2024;18:2261\u201378. https:\/\/doi.org\/10.1021\/acsnano.3c10109.","journal-title":"ACS Nano"},{"key":"2538_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00950-1","author":"W Jing","year":"2025","unstructured":"Jing W, Han M, Wang G, Kong Z, Zhao X, Fu Z, et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat Cancer. 2025. https:\/\/doi.org\/10.1038\/s43018-025-00950-1.","journal-title":"Nat Cancer"},{"key":"2538_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/d41573-020-00053-9","volume":"19","author":"MT Villanueva","year":"2020","unstructured":"Villanueva MT. Macrophages get a CAR. Nat Rev Drug Discov. 2020;19:308. https:\/\/doi.org\/10.1038\/d41573-020-00053-9.","journal-title":"Nat Rev Drug Discov"},{"key":"2538_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","volume":"7","author":"B Sun","year":"2019","unstructured":"Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 2019;7:1813\u201323. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0026.","journal-title":"Cancer Immunol Res"},{"key":"2538_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-024-00553-z","volume":"13","author":"Q Mai","year":"2024","unstructured":"Mai Q, He B, Deng S, Zeng Q, Xu Y, Wang C, et al. Efficacy of NKG2D CAR-T cells with IL-15\/IL-15R\u03b1 signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder. Exp Hematol Oncol. 2024;13:85. https:\/\/doi.org\/10.1186\/s40164-024-00553-z.","journal-title":"Exp Hematol Oncol"},{"key":"2538_CR36","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Kerre T, Havelange V, Poir\u00e9 X, Lewalle P, Wang ES, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10:e191\u2013202. https:\/\/doi.org\/10.1016\/S2352-3026(22)00378-7.","journal-title":"Lancet Haematol"},{"key":"2538_CR37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","volume":"80","author":"H Dai","year":"2024","unstructured":"Dai H, Zhu C, Huai Q, Xu W, Zhu J, Zhang X, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024;80:913\u201327. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.034.","journal-title":"J Hepatol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02538-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02538-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02538-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:03:06Z","timestamp":1767974586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02538-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2538"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02538-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments and handling of mice were conducted under the Animal Experiment Ethics Committee of the Fourth Military Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}